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A B S T R A C T
Objectives: Febrile neutropenia (FN) is a common but lethal complication of chemotherapy in
hematological malignance. The aim of this study was to identify the prognostic risk factors for
antibiotic treatment outcome in PN patients, and provide the optimal choice for the initial empirical
antibiotic treatment.
Methods: 227 consecutive FN hematologic malignancies from four hospitals in Northeast China were
enrolled. The outcome of antibiotic therapy was investigated until 14 days after the onset of FN. The
factors affecting antibiotic therapy outcome were evaluated using Univariate analysis and Multivariate
logistic regression analysis.
Results: Among all patients, 27 patients did not achieve favorable outcome either clinically or
bacteriologically. It was shown that the risk factors for poor FN therapy outcome were associated with
prolonged duration of neutropenia over 9 days during FN (P=0.019), slow neutrophil recovery (P=0.039),
respiratory infection (P=0.005), and that initial monotherapy with drugs recommended by the guidelines
indicated better outcome (P=0.009). Additionally, patients with multi-bacterial infection, as well as
further ANC decrease after fever, had a poor prognosis.
Conclusions: Our results indicate that early application of antibiotics and prevention of respiratory
infection as well as good clinical care are able to improve clinical outcomes from empirical antibiotic
treatment in FN patients with hematological malignances.
 2015 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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Febrile neutropenia (FN) represents a common but potentially
lethal complication of chemotherapy in patients with hematologi-
cal malignances1–3. Several studies have been performed in order* Corresponding author. Institute of Hematology and Blood Diseases Hospital,
Chinese Academy of Medical Sciences and Peking Union Medical College,
288 Nanjing Road, Tianjin 300060, China. Tel.: +86022-23909180.
E-mail addresses: zhaiweihua@eyou.com (W. Zhai), lovingyvonne@163.com
(X. Zhang), katewjl@medmail.com.cn (J. Wei), kachydeng@hotmail.com (Q. Deng),
sdsgr@sina.com (X. Dong), xiaoleixueye@126.com, 916799667@qq.com (X. Zhang),
zoexin@126.com (G. Zhang), maqiaoling88@126.com (Q. Ma),
zhangeongli333@sina.com (R. Zhang), sudong1026@126.com (D. Su),
sizhoufeng@medmail.com.cn (S. Feng), mzhan@medmail.com.cn (M. Han).
1 These authors contributed equally to this work.
http://dx.doi.org/10.1016/j.ijid.2015.04.015
1201-9712/ 2015 The Authors. Published by Elsevier Ltd on behalf of International So
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to select better intervention for clinical practice. Some previous
studies have demonstrated that prolonged neutropenia correlates
with worse outcome in FN4,5; however, inconsistent results
regarding the effect of different durations of neutropenia on the
outcome of FN still exist. In addition, because the symptoms and
signs of inﬂammation are typically attenuated or even absent in a
signiﬁcant majority of FN patients, whether the documented
clinical infection site can be considered as one of the prognostic
risk factors was still controversial6,7.
As the majority of infections in FN are predominantly Gram-
negative, third generation cephalosporin, carbapenems or cepha-
losporin with anhydrase inhibitors have been recommended as the
optimal initial choice for empirical therapy8,9. Although rapid and
accurate antibiotic regimens in the ﬁrst line could ensure better
outcome in FN patients, increasing incidence of antibioticciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
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improved treatment strategies in FN patients, especially for the
initial empirical approach. While monotherapy has become the
standard regimen in the empirical approach10,11, it is still unclear
whether combination therapy should be used to prevent the
development of multiple drug resistance (MDR)12,13.
In this multicenter prospective observational study, 227 cases
of FN with hematological malignances in Northeast China have
been analyzed in order to determine the predictors of outcome of




This prospective observational study was conducted in multiple
centers in Northeast China including 4 tertiary hospitals: Institute
of Hematology and Blood Diseases Hospital of Chinese Academy of
Medical Sciences and Peking Union Medical College, the ﬁrst center
hospital of Tianjin, the Qilu afﬁliated hospital of Shandong medical
school and the second afﬁliated hospital of Hebei medical
university, which were abbreviated to X, Y, Q, and H respectively.
All patients were diagnosed with hematologic malignances,
including acute or chronic leukemia, Hodgkin or non-Hodgkin
lymphoma, myelodysplastic syndrome, multiple myeloma, and
others from April 2013 to August 2013. No ﬂuoroquinolone
prophylaxis was used for neutropenic patients. This study was
approved through the ethics review process by the Institutional
Review Board. Written informed consent was obtained from all
registered patients before the study protocol was implemented.
2.2. Diagnostic deﬁnition
The febrile neutropenia was diagnosed with both parameters of
fever and neutropenia as follows: (1) a single axillary temperature
 38.3 8C or a temperature 37.8 8C sustained over a 1-h period,
and (2) an absolute neutrophil count (ANC)  500 cells/mm3 or an
ANC that was expected to decrease to 500 cells/mm3 during the
following 48 h. Preindex characteristics (age and sex), and selected
risk factors such as primary hematology disease, infectious history
within a month before enrollment, especially the neutropenia
duration including the whole phase of neutropenia, neutropenia
before fever, as well as febrile neutropenia duration were
evaluated. Complete blood count, blood urea nitrogen (BUN),
creatinine, AST, ALT, bilirubin and albumin were examined before
chemotherapy and on the initial day of FN. If a fever developed, at
least two blood cultures, and, if appropriate, cultures from other
suspected body sites were carried out. Additional blood cultures
were performed if the patient’s fever was sustained. The lowest
leukocyte count and its change trend were recorded. For all strains
isolated, the antibiograms were primarily determined with the
disk diffusion method standardized according to the Swedish
Reference Group for Antibiotics (SRGA). Pathogen isolates were
classiﬁed either as susceptible (S), intermediate (I), or resistant (R),
according to the SRGA breakpoints.
2.3. Therapeutic effect assessment
Three antibiotic treatment regimens were used in this study:
Monotherapy with drugs recommended by the Guideline including
Cefepime, Ceftazidime, Piperacillin/Tazobactam, Sulbactam/Cefop-
crazone, Meropenem and Imipenem (reference), Monotherapy with
non-recommended drugs and combination therapy with Guideline
recommended drugs plus others such as Teicoplanin or Linezolid.
The therapeutic outcome with antibiotics was followed-up for14 days after the onset of fever in the neutropenic patients. Patient
data were collected, including baseline information, and a stan-
dardized case report form was used to evaluate antibiotic
therapeutic outcome by researchers who were not involved in the
study. Treatment effect was evaluated by clinical manifestation and
microbiological results. The success of antibiotic therapy, labeled ‘‘a
favorable outcome’’, was deﬁned as defervescence at least for 3 days
without any sign of persistent infection, and no pathogen growth or
fungus in culture of different samples. If the outcome did not meet
the described criteria, it was diagnosed as failure of antibiotic
therapy or poor/unfavorable outcome.
2.4. Statistical analysis
Univariate analysis was performed for each episode variable,
with poor outcome as the dependent variable. Multivariate logistic
regression analysis was performed in order to identify indepen-
dent predictors of poor outcome. We used the SAS program to
conﬁrm model reliability and validity by multi-collinearity
analysis. A tolerance (TOL) below 0.1 was considered as having
multi-collinearity. The SAS 9.2 software was used for all the
statistical analysis. All the tests were two-tailed, and a P value
below 0.05 was considered statistical signiﬁcance.
3. Results
3.1. Patient characteristics
Two hundred and twenty seven FN patients with hematologic
malignances were enrolled. Baseline characteristics were summa-
rized in Table 1. The median patient age was 38 years (18-78), and
the male to female ratio was 1.29:1. Diseases presented were acute
leukemia, myelodysplastic syndrome (MDS), chronic myelogenous
leukemia (CML), multiple myeloma (MM) and other hematological
malignances. Most patients received standard or high dose of
chemotherapy; 5.7% of patients had maintenance therapy. Seventy
three patients had co-morbidity diseases. The most common co-
morbidity was respiratory system disease (9.25%), followed by
cardiovascular disorders. The majority of FN occurred after
chemotherapy in hospitals; 15.4% of patients contracted FN
outside the hospitals. 162 patients had central venous catheters
and 46.7% of patients had infection history within one month.
3.2. Overall outcome evaluation
The overall failure rate from antibiotic treatment was 11.9%
(27 cases) and the mortality rate was 0.8% (2 patients) in this study.
Among those patients, 12 were clinically diagnosed as probable
invasive fungal infection. After antibiotic treatment, the outcome
was no different with respect to gender, fever onset out of the
hospitals, indwelling time of central venous catheter, disease
status, MASCC risk, chemotherapy regimen for hematological
malignances, or pre-infection history (Table 2 and Table 3).
Although 12.6% of patients (26 cases) at age less than 60 had a
higher unfavorable outcome than patients (n=1, 4.8%) over 60 years
old, no statistical signiﬁcance was reached (Tables 2 and 3, p >0.3).
3.3. The effect of antibiotic treatment regimens on outcome
For antibiotic treatment, three regimens were applied in this
study: monotherapy with drugs recommended by the Guideline,
monotherapy with drugs beyond the Guideline and combination
therapy. 8.4% (n=13) and 14.8% (n=4) of patients had poor results
after treatment with monotherapy with drugs recommended by
the Guideline and combination therapy, respectively (p>0.1,
Tables 1–3). Signiﬁcantly higher incidence of favorable outcome
Table 1







X 114 23 137
H 26 1 27
Q 22 2 24
Y 38 1 39
Sex
Male 110 18 128
Female 90 9 99
Fever onset
Outside the hospital 30 5 35
Nosocomial infection 170 22 192
Central-venous catheter
Yes 145 17 162
No 55 10 65
Diagnosis
AML 141 21 162
ALL 45 3 48
MDS 5 3 8
MM 1 0 1
CML 5 0 5
Co-morbidity disease
No 135 19 154
Cardio-vascular system 8 1 9
Respiratory system 19 2 21
Digestive or urinary system 6 1 7
others 19 3 22
missing 13 1 14
MASCC score
High risk 59 11 70
Low risk 141 16 157
Disease Status
Controlled 123 13 136
Uncontrolled 77 14 91
Chemotherapy
Standard dose 141 21 162
High dose 42 4 46
Maintenance 17 2 19
Infectious history
Yes 91 15 106
No 109 12 121
Abbreviations: X, Institute of Hematology and Blood Diseases Hospital of Chinese
Academy of Medical Sciences and Peking Union Medical College; Y, the ﬁrst center
hospital of Tianjin; Q, afﬁliated Qilu hospital of Shandong medical school; H, the
second afﬁliated hospital of Hebei medical university; MASCC score, Multinational
Association for Supportive Care in Cancer; AML, acute myelogenous leukemia; ALL,
acute lymphocte leukemia; MDS, myelodysplastic syndrome; MM, multiple
myeloma; CML, chronic myelogenous leukemia.
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Male 110(85.9) 18(14.1) 128
Female 90(90.1) 9(9.9) 99
Fever onset
Outside the hospital 30(85.7) 5(14.3) 35
Nosocomial infection 170(88.5) 22(11.5) 192
Central-venous catheter
Yes 145(89.5) 17(10.5) 162
No 55(84.6) 10(15.4) 65
Age
 60 180(87.4) 26(12.6) 206
>60 20(95.2) 1(4.8) 21
Co-morbidity disease
No 135(87.7) 19(12.3) 154
Cardio-vascular system 8(88.9) 1(11.1) 9
Respiratory system 19(90.4) 2(9.6) 21
Digestive or urinary system 6(85.7) 1(14.3) 7
others 19(86.4) 3(13.6) 22
missing 13(92.6) 1(7.4) 14
MASCC score
High risk 59(84.3) 11(15.7) 70
Low risk 141(89.8) 16(10.2) 157
Disease Status
Controlled 123(90.4) 13(9.6) 136
Uncontrolled 77(84.6) 14(15.4) 91
Chemotherapy
Standard dose 141(87.0) 21(13.0) 162
High dose 42(91.3) 4(8.7) 46
Maintenance 17(89.5) 2(10.5) 19
infectious history
Yes 91(85.8) 15(14.2) 106
No 109(90.1) 12(9.9) 121
ANC decline*
Yes 81(82.7) 17(17.3) 98
No 119(92.2) 10(7.8) 129
ANC recovery*
Increase* 185 (91.5) 17 (8.5) 202
Decline 15 (60) 10 (40) 25
Neutropenia pre-fever
>2d 107(87.7) 15(12.3) 122
2d 92(89.3) 11(10.7) 103
Missing 1(50.0) 1(50.0) 2
FN duration*
>9d 62(78.5) 17(21.5) 79
9d 134(93.7) 9(6.3) 143
Missing 4(80.0) 1(20.0) 5
Bacterium*
G- 41(91.1) 4(8.9) 45
G+ 11(78.6) 3(21.4) 14
Multi-bacterial* 25(75.8) 8(24.2) 33
Unidentiﬁed 123(91.1) 12(8.9) 135
Infection site*
Not respiratory 69(95.8) 3(4.2) 72
Respiratory* 92(80.7) 22(19.3) 114
Unidentiﬁed 39(95.1) 2(4.9) 41
Antibiotics*
Combination 23(85.2) 4(14.8) 27
Recommended Mono-* 141(91.6) 13(8.4) 154
Not recommended Mono- 36(78.3) 10(21.7) 46
Anti-coccus
Yes 81(83.5) 16(16.5) 97
No 119(91.5) 11(8.5) 130
Abbreviations: MASCC score, Multinational Association for Supportive Care in
Cancer; ANC decline, ANC continue to decline after fever; ANC Recovery: ANC
during the day 1014 after chemotherapy when compared to the lowest count of
ANC during therapy.
* indicates the statistical signiﬁcance for the factors (refer to Table 3).
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monotherapy drugs (OR=0.124, p=0.009, Tables 2 and 3).
3.4. The effect of neutropenia on outcome of antibiotics treatment
It is well known that the severity and duration of neutropenia
impact the therapeutic outcome of antibiotics. In this study, the
median neutropenia duration was 11 days (1-69 days, Table 2). To
predict the effect of neutropenia on antibiotics treatment, we
studied three aspects: the durations of neutropenia before and
after fever occurrence, as well as the trend of neutropenia after
fever. It was shown that neutropenia duration before fever and the
whole duration of neutropenia were not associated with the
treatment response in FN patients. Patients with longer duration of
neutropenia after fever (more than 9 days) had poor antibiotic
treatment outcome (p0.005, Tables 2 and 3). After chemotherapy,
the kinetics of ANC recovery also played a role in achieving
favorable outcome. The ANC increase during day 10-14 after
chemotherapy was observed in 185 patients with favorable
outcome (92.5%), however, only 17 patients (63%) with unfavor-
able outcome had ANC increase during this period (p=0.039,Tables 2 and 3). Although multivariant analysis did not reveal the
relationship between ANC decrease after fever with antibiotic
treatment outcome, the patients with further ANC decrease after
fever had unfavorable outcomes with univariate analysis
(p=0.0308, Tables 2 and 3).
Table 3
Univariant and multivariant analyses of FN outcome
Item Univariant analysis Multivaiant analysis
OR P 95% CI OR P 95% CI
Sex
Female 0.611 0.254 0.262 1.426 0.336 0.127 0.083 1.365
Male Reference - - - Reference - - -
Age
<=60y 0.346 0.310 0.045 2.689 153.804 0.577 <0.001 >999.99
>60y Reference - - - Reference - - -
Infection Onset place
Nosocomial 0.776 0.635 0.273 2.20 0.799 0.820 0.115 5.543
Outside hospital Reference - - - Reference - - -
Disease Status
Uncontrolled 1.72 0.187 0.768 3.855 0.985 0.983 0.234 4.140
Controlled Reference - - - Reference - - -
Chemotherapy
High-dose 0.639 0.435 0.208 1.966 1.931 0.471 0.322 11.572
Maintenance 0.79 0.763 0.17 3.667 1.979 0.578 0.178 21.963
Standard dose Reference - - - Reference - - -
MASCC score
Low risk 0.609 0.238 0.267 1.39 0.453 0.266 0.112 1.831
High risk Reference - - - Reference - - -
Pre-infection history
No 0.681 0.352 0.304 1.529 1.023 0.973 0.264 3.961
Yes Reference - - - Reference - - -
ANC decline trend at the beginning 2.498 0.030 1.088 5.731 1.357 0.682 0.315 5.852
ANC recovery 0.138 <.0001 0.054 0.353 0.167 0.039 0.030 0.920
Duration of neutropenia before fever
>2d 1.021 0.151 0.992 1.051 1.102 0.449 0.856 1.419
<=2d Reference - - - Reference - - -
Duration of FN
>9d 4.082 0.001 1.724 9.669 5.456 0.019 1.315 22.638
<=9d Reference - - - Reference - - -
Pathogenic bacterium
G- 1 1 0.306 3.272 1.774 0.542 0.280 11.228
G+ 2.796 0.152 0.684 11.422 1.508 0.745 0.126 18.116
Multi-bacteria 3.28 0.019 1.216 8.851 3.675 0.107 0.752 17.950
No documented Reference - - - Reference - - -
Infection site
Not respiratory infection 0.848 0.859 0.136 5.295 1.230 0.878 0.087 17.443
Respiratory infection 4.663 0.043 1.045 20.798 30.181 0.005 2.801 325.217
Unknown of origin Reference - - - Reference - - -
Initial antibiotic therapy
Combination 1.886 0.301 0.566 6.289 1.264 0.850 0.111 14.359
Not recommended Reference - - - Reference - - -
Mono-drug 0.332 0.016 0.135 0.818 0.124 0.009 0.026 0.606
Anti-coccus 0.626 0.740 0.175 2.234 0.914 0.898 0.230 3.639
Abbreviations: MASCC score, Multinational Association for Supportive Care in Cancer; ANC decline, ANC continue to decline after fever; ANC Recovery: ANC during the day
1014 after chemotherapy when compared to the lowest count of ANC during therapy; Mono-drug, mono-drug recommended by the Guideline, including Cefepime,
Ceftazidime, Piperacillin/Tazobactam, Sulbactam/Cefopcrazone, Meropenem and Imipenem.
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Of the 227 patients, no infection sites were found in 39 (16.74%)
patients (Table 2). The most common infection site was the
respiratory tract (114 patients, 50%, Table 2), followed by multi-
site infections. No difference was shown for antibiotic treatment
outcome between patients with documented infection sites and
those without clear infection (p>0.05, Table 3). However, in
patients with respiratory infections, 22 patients (19.3%) had
unfavorable outcomes, whereas a poor outcome was only found in
4.2% (n=3) and 4.9% (n=2) of patients with non-respiratory
infection or no documented infection, respectively (p<0.05,
Tables 2 and 3).
In our study, all 12 cases with BSI achieved favorable outcomes
(Table 4). One BSI patient did not have a central venous catheter.
No catheter infection was diagnosed in the other 11 patients. The
low rates of catheter infection may be attributed to valid and strict
nursing procedure. Seven of the 12 BSI patients had a previous
infection before enrollment. The median neutropenia duration for
BSI patients was 7 days, similar to the total group. One BSI patientsreceived meropenem plus linezolid because of the previous G+
bacterium infection, and others received monotherapy of drugs
recommended by the guidelines.
3.6. Pathogen survey and drug resistance result
We have carried out 492 episodes of bacterium culture in
227 patients; the pathogens were isolated from 169 episodes
(Table 5). Gram-negative bacteria were isolated in 116 episodes
(68.64%) from 45 patients, with Escherichia being the most
common (Table 5). 14 patients had Gram-positive bacterial
infection, which accounted for 31.36% of pathogen positive
episodes; Staphylococcus epi., E. faecalis and Enterococcus faeium
were the most common G+ bacteria (Table 5). The outcome from
antibiotic treatment was comparable in patients with G- bacteri-
um infection and those without isolated bacterium (8.9% for both);
however, a poor result was observed in patients with multiple
bacterial infections (24.2%,, p<0.05 when compared to patients
with no bacterium infection, Table 3). Among isolated G- bacteria,
all except pseudomonas and stenotrophomonas maltrophilia were
Table 4
Patients with BSI
No center sex age Central-venous catheter MASCC score Duration of neutropenia(day) Pathogens isolated
1 X Male 31 Yes High-risk 13 Escherchia coli.
2 X Male 74 Yes Low-risk 14 Escherchia coli.
3 X Male 20 Yes High-risk 3 Klebsiella.
4 X Male 29 Yes Low-risk 6 Escherchia coli.
5 X Male 47 No Low-risk 14 Enterobacter.
6 X Male 45 Yes Low-risk 4 Enterobacter.
7 X Male 20 Yes High-risk 6 Staphylococcus. epidermidis
8 X Male 30 Yes Low-risk 5 Klebsiella.
9 X Male 25 Yes High-risk 9 Escherchia coli.
10 X Male 39 Yes High-risk 7 Klebsiella.
11 X Female 33 Yes Low-risk 7 Klebsiella.
12 Y Female 20 Yes Low-risk 10 Escherchia coli.
Abbreviations: X, Institute of Hematology and Blood Diseases Hospital of Chinese Academy of Medical Sciences and Peking Union Medical College; Y, the ﬁrst center hospital
of Tianjin; Q, afﬁliated Qilu hospital of Shandong medical school; H, the second afﬁliated hospital of Hebei medical university; MASCC score, Multinational Association for
Supportive Care in Cancer.
Table 5
Isolated bacterium from 492 episodes in 227 patients with documented infection
sites
Isolated bacterium No. %
G- 116 68.64








Serratia marcescens 3 1.78
Areomonas. 3 1.78
G+ 53 31.36
Staphylococcus aureus 4 2.37
Staphylococcus epidermidis. 16 9.47
Enterococcus faeium 8 4.73
Enterococcus faecalis 12 7.10
Enterococcus avium 1 0.59
Hemolytic strepcocci 9 5.33
Staphylococcus hominis 2 1.18
Leukonoid 1 0.59
W. Zhai et al. / International Journal of Infectious Diseases 37 (2015) 97–103 101susceptive to imipenem and meropenem. It was demonstrated that
all strains of G- bacteria isolated from some patients were
ceftazidime resistant (Table 6). All G+ bacteria were sensitive to
vancomycin, teicoplanin, linezolid and tigecycline. Some G+
bacteria were resistant to ciproﬂoxacin (Table 6).Table 6
Resistance of Gram-negative and Gram-positive bacteria
Species
Gram-negative ciproﬂoxacin TZP 
Escherchia coli. 15(40.54%) 2(5.1%) 
Klebsiella. 3(12%) 1(4.2%) 
Pseudomons. 0 1(7.1%) 
Acinetobacter. 0 0 
Enterobacter. 3(37.5%) 0 
Stenotrophomonas maltrophilia - - 
Gram-positive bacteria ciproﬂoxacin vancomycin 
Staphylococcus aureus 2(50%) 0 
Staphylococcus epidermidis. 2(12.5%) 0 
Enterococcus faeium 6(100%) 0 
Enterococcus faecalis 2(18.2%) 0 
Hemolytic strepcocci 7(77.8%) 0 
Abbreviations: TZP, Piperacillin -Tazobactam.4. Discussion
In this study, we demonstrated that a favorable outcome with
empirical antibiotic treatment was obtained in FN patients with
hematological malignancies from four centers in Northeast China
when patients had short periods of neutropenia without docu-
mented respiratory infection after chemotherapy for primary
diseases. The continuous decline of ANC after fever and slow
neutrophil recovery as well as the presence multi-bacterial
infection signiﬁcantly impact antibiotic treatment outcome.
Although both degree and duration of neutropenia have been
considered as vital factors inﬂuencing antibiotic therapy effects in
neutropenia patients, some other studies have shown different
results. Rosa, et al. found that several other factors, including
relapsed underlying disease status, were independently associated
with mortality within 28 days, but not the duration of
neutropenia14. Similar results were obtained by Yong Park and
colleagues15. In our study, we separated the duration of
neutropenia into two stages based on the onset of fever:
neutropenia before FN and neutropenia duration after fever. In
univariate analysis, neither the whole duration of neutropenia nor
neutropenia duration before FN was associated with the patient’s
outcome. However, prolonged neutropenia after fever lasting more
than 9 days was identiﬁed as one of the risk factors for poor
outcome. Additionally, it is worth noting that the kinetics of ANC
recovery also impact FN patients’ outcome: it holds true that early
ANC recovery leads to better outcome. Furthermore, an unfavor-
able outcome was observed when ANC continued to decline after
fever in univariate analysis (OR=2.498, P=0.030), although thisceftazidime Cefepime imipenem meropenem
5(27.8%) 2(5%) 0 0
2(25%) 2(8%) 1(4%) 1(4%)
1(7.1%) 1(6.7%) 2(13.3%) 2(13.3%)
2(18.2%) 0 0 0
2(22.2%) 2(22.2%) 0 0
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P=0.682). As the tendency of ANC to decline is observed in the very
early stages of FN, it would be a promising prognostic factor to
predict antibiotic treatment responses.
In spite of reduced absolute neutrophil count (ANC), lack of
signs or symptoms and the low positive rates of bacterium
isolation make it hard to ﬁnd the clear infection site in FN patients.
No documented infection sites usually have better prognostics
after antibiotics treatment. Klastersky, et al. reported that
mortality was 13% in FN patients without a clinical site of infection
and 23% with documented infection sites16. In contrast to the
above observation, no difference was obtained for antibiotic
treatment results regardless of clear infection site or not, which
may be attributed to effective and early antibiotics application in
our study. It is interesting to note that patients with respiratory
infection had worse outcomes than those with no infection site
identiﬁed during FN in this study (OR=31.181, P=0.005). The same
observation was demonstrated in other studies17.
Bloodstream infection (BSI) has been considered as a risk factor
of FN unfavorable outcome18–21. Surprisingly, all 12 cases with BSI
achieved favorable results in our research. The most common
bloodstream isolate was Escherichia coli, followed by Klebsiella
pneumonia, and Staphylococcus. epi., which is in good agreement
with the study conducted by Ali. N and collegues22. Similar results
were also observed in another retrospective research study23;
E.coli was more common in the neutropenic group when compared
to the non-neutropenic one (22.7% vs 2.5%.p<0.001). It is well-
accepted that the translocation of gut organisms is the major cause
for E.coli BSI. In this study, no BSI case was identiﬁed in catheter-
related episodes even though staphylococcus epi was isolated in one
patient. This result implicates that timely checking and strict care
reduce catheter related infection.
Empirical therapy with antimicrobials is always used in
patients with FN, even without clear microbiological evidence.
Previous meta-analysis has suggested that empirical monotherapy
of third generation cephalosporins and carbapenems was as
effective, or even more effective, than combination
therapy12,13. The Guideline of antibiotics drugs for FN patients
has recommended sulbactam/cefopcrazone, piperacillin/tazobac-
tam, cefepime, ceftazidime or carbapenem including meropenem
and imipenem as the ﬁrst choice for the initial
treatment4,11,13. However, many clinicians would rather choose
a combination regimen for FN patients comparable with a low-risk
one based on availability, costs, ease of administration and local
antibiogram. For example, in a prospective research study that
involved 2092 bacteraemias in neutropenic patients, empirical
therapy with amikacin was reported to be associated with lower
mortality (OR 0.50, p=0.016)24. In this study, we compared
antibiotic treatment outcome from 3 regimens: monotherapy
with antibiotics recommended from the Guideline, combination
therapy, and the monotherapy with ﬂuoroquinolone, amikacin and
other third generation cephalosporins. Multivariate analysis
showed that monotherapy with antibiotics recommended by the
Guideline as initial therapy could beneﬁt FN patients by reducing
the risk of treatment failure, compared with the regimen of
antibiotics beyond the recommendation. Additionally, the combi-
nation regimen had no advantages over monotherapy with
recommended antibiotics. Based on the results from the bacterial
etiology and antibiogram, no drug resistant bacterium was isolated
after treatment with our regimens. These results suggest that the
monodrug regimen with cefepime, ceftazidime, carbapenem,
sulbactam/cefopcrazone or piperacillin/tazobactam is the optimal
initial approach in empirical treatment. Although there was no
signiﬁcant difference for achieving a favorable outcome between
patients with G+ isolates and patients without documented
infection sites, due to limited number of patients with G+bacterium, we did not perform further analysis to evaluate the
role of monotherapy. However, based on the sensitivity of G+
isolates to antibiotics, the combination therapy should be
recommended if a Gram-positive infection exists. Vancomycin
and other anti-coccus drugs should not be routinely used as part of
initial empirical therapy, but would achieve a favorable outcome
when pathogen is isolated25.
In conclusion, the outcome of antibiotic treatment in FN
patients with hematological malignancies after chemotherapy was
closely related to the duration of neutropenia, the kinetics of
neutrophil recovery, respiratory infection and utilization of
empirical therapy with drugs recommended by the Guideline.
Good clinical practice with optimization of the inpatient environ-
ment and strict patient care decreases the risk of unfavorable
outcomes from antibiotic treatment. Early application of empirical
drugs and effective prophylaxis of respiratory infection will
improve overall clinical results.
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